Press Release Courtesy of EIN Presswire and Ad Scientiam. The ME&MGopen study has already recruited 165 patients in the USA and 11 in Canada. This innovative program is supported by Alexion, AstraZeneca Rare Disease. PARIS, FRANCE, September 21, 2023 /EINPresswire.com/ — Generalized Myasthenia Gravis (gMG) is a chronic autoimmune neuromuscular disease that causes fatigue and … Read more

Are you interested in advancing treatments in Parkinson’s disease? Did you know that the non-motor symptoms of Parkinson’s disease are often very disabling and can lead to poor outcomes with the disease? If you have Parkinson’s disease, you may be eligible to take part in a research study to learn if we can use non-invasive … Read more

This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of CBD administered as ZYN002, a transdermal gel, for the treatment of children and adolescent patients with FXS. Status: Not currently enrolling

A study is being conducted to understand the effectiveness of ALXN2050 compared with placebo in the treatment of generalized MG (gMG) based on improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score. Status: Open

This is a genetic registry study aimed at developing a central location to store Parkinson’s Disease genetic data for future research use. Status: Open

Circadian rhythm is well known to affect various aspects of sports performance; however, the sport-specific effects in rock climbing are not well studied. We aim to evaluate diurnal changes in maximum finger strength, finger endurance, and power in rock climbers. Status: Not currently enrolling

This study aims to test the safety and effectiveness of batoclimab in treating patients with Myasthenia Gravis. Status: Open

James F. Howard Jr., MD, professor in the UNC Department of Neurology, was lead investigator in UCB’s RAISE trial to evaluate zilucoplan as a treatment for generalized myasthenia gravis in adults.

James F. Howard Jr., MD, professor in the UNC Department of Neurology, was principal investigator of the phase 3 trial for the experimental drug efgartigimod, developed by Belgian pharmaceutical company Argenx.

Over 800 scientists from across the United States and overseas convened virtually for a joint Duke/UNC Alzheimer’s Disease Symposium on May 27.